详情页 - 河北医科大学第四医院机构库

当前位置：首页 > 详情页

Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.

5| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Graduate School of Hebei Medical University, Shijiazhuang, China. [2]Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China. [3]Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang, China. [4]The Third Hospital of Hebei Medical University, Shijiazhuang, China. [5]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [6]Hebei Northern University, Zhangjiakou, China.

出处：

DOI：

ISSN：

关键词： liver enzymes liver fat liver fibrosis meta‐ analysis non‐ alcoholic fatty liver disease sodium– glucose cotransporter 2 type 2 diabetes mellitus

摘要：

This study aimed to analyze the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the indexes of liver fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease, and also to observe the effects on liver enzymes and liver fat. This meta-analysis was performed using RevMan 5.3 statistical software. SGLT2 inhibitors could significantly reduce the level of hepatic fibrosis index: fibrosis-4 (mean difference [MD] 0.25, 95% CI -0.39 to -0.11, p = 0.0007); serum type Ⅳ collagen 7s (MD 0.32, 95% CI -0.59 to -0.04, p = 0.02); and ferritin (MD 26.7, 95% CI 50.64, 2.76, p = 0.03). SGLT2 inhibitors could significantly reduce the level of liver enzymes: alanine aminotransferase (MD 3.49, 95% CI -5.1 to 1.58, p < 0.0001); aspartate aminotransferase (MD 3.64, 95% CI -5.10 to -2.18, p < 0.00001); and glutamate aminotransferase (MD 7.13, 95% CI -12.95 to -1.32, p = 0.02). SGLT2 inhibitors could significantly reduce the level of liver fat: liver-to-spleen attenuation ratio (MD 0.16, 95% CI 0.10-0.22, p < 0.00001); magnetic resonance imaging proton density fat fraction (MD 1.97, 95% CI -3.49 to -0.45, p = 0.01); liver controlled attenuation parameter (MD 0.29, 95% CI -26.95 to -13.64, p < 0.00001); liver fat score (MD 0.55, 95% CI 1.04 to -0.05, p = 0.03); and liver fat index (MD 11.21, 95% CI -16.53 to -5.89, p < 0.0001). SGLT2 inhibitors could improve liver fibrosis, liver enzymes, liver fat, and metabolic indexes in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. © 2021 Japan Society of Hepatology.

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区胃肠肝病学

最新[2025]版：

大类 | 3 区医学

小类 | 4 区胃肠肝病学

JCR分区：

出版当年[2021]版：

Q2 GASTROENTEROLOGY & HEPATOLOGY

最新[2023]版：

Q1 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 3.9 最新[2023版] 3.3 最新五年平均 4.942 出版当年[2021版] 3.871 出版当年五年平均 4.288 出版前一年[2020版] 4.2 出版后一年[2022版]

第一作者：

第一作者机构： [1]Graduate School of Hebei Medical University, Shijiazhuang, China. [2]Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.

通讯作者：

通讯机构： [1]Graduate School of Hebei Medical University, Shijiazhuang, China. [2]Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China. [3]Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang, China. [*1]Graduate School of Hebei Medical University, Department of Endocrinology, Hebei General Hospital, Shijiazhuang, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.

文献详情

相关文献